Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force | SpringerLink
Recent updates on GLP-1 agonists: Current advancements & challenges - ScienceDirect
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action - ScienceDirect
GLP-1 analogs
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology
A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 - Czech - 2018 - Hepatology
Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control | Hypertension
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists | Cardiovascular Diabetology | Full Text
Neurotrophic effects of exenatide is mediated by TrkB signalling in... | Download Scientific Diagram
Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity | Bentham Science
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. - Abstract - Europe PMC